By the end of 2017, CTS has secured three source plasma partners and continues to seek additional partners in the plasma industry in order to continue to diversify CTS’s revenue stream.
In August, the CTS Tampa lab transitioned to the same laboratory information systems (LIS) as the Da...
Transitioned all 6 CTS labs from an investigational new drug (IND) to a licensed Zika test, and anno...
Transitioned all 5 CTS labs from an investigational new drug (IND) to a licensed pooled Babesia test...
In October, due to demand from existing healthcare partners, CTS began testing blood donors for anti...
CTS Research Consortium was established to further CTS’s leadership in infectious disease research....
In 2016, CTS tested more source plasma samples (4.9 million) than blood donor samples (4.5 million).